Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
FZD7 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | O75084 |
|---|---|
| Clone Names | 91009141 |
| Gene ID | 8324 |
|---|---|
| Other Names | Frizzled-7, Fz-7, hFz7, FzE3, FZD7 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | FZD7 |
|---|---|
| Function | Receptor for Wnt proteins. Most frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. Activation by WNT8 induces expression of beta-catenin target genes (By similarity). Following ligand activation, binds to CCDC88C/DAPLE which displaces DVL1 from FZD7 and leads to inhibition of canonical Wnt signaling, activation of G-proteins by CCDC88C and triggering of non-canonical Wnt responses (PubMed:26126266). May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. |
| Cellular Location | Cell membrane; Multi-pass membrane protein. Endosome membrane; Multi-pass membrane protein. Note=Associated to the plasma membrane in the presence of FZD7 and phosphatidylinositol 4,5-bisphosphate (PIP2). Localized in recycling endosomes in other conditions |
| Tissue Location | High expression in adult skeletal muscle and fetal kidney, followed by fetal lung, adult heart, brain, and placenta Specifically expressed in squamous cell esophageal carcinomas |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Members of the 'frizzled' gene family encode7-transmembrane domain proteins that are receptors for Wntsignaling proteins. The FZD7 protein contains an N-terminal signalsequence, 10 cysteine residues typical of the cysteine-richextracellular domain of Fz family members, 7 putative transmembranedomains, and an intracellular C-terminal tail with a PDZdomain-binding motif. FZD7 gene expression may downregulate APCfunction and enhance beta-catenin-mediated signals in poorlydifferentiated human esophageal carcinomas.
References
Guey, L.T., et al. Eur. Urol. 57(2):283-292(2010)Vincan, E., et al. Dev. Dyn. 239(1):311-317(2010)Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :Hosgood, H.D. III, et al. Respir Med 103(12):1866-1870(2009)Ueno, K., et al. Br. J. Cancer 101(8):1374-1381(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
